The Friedewald Formula Underestimates LDL Cholesterol at low Concentrations
暂无分享,去创建一个
W. März | H. Scharnagl | H. Wieland | M. Nauck | M. Nauck | Winfried März
[1] N. Rifai,et al. Analytical and clinical performance of a detergent-based homogeneous LDL-cholesterol assay: a multicenter evaluation. , 2000, Clinical chemistry.
[2] D. Waters,et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. , 1999, The New England journal of medicine.
[3] W. März,et al. Safety of low-density lipoprotein cholestrol reduction with atorvastatin versus simvastatin in a coronary heart disease population (the TARGET TANGIBLE trial). , 1999, The American journal of cardiology.
[4] R. Collins,et al. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.
[5] J. Pincus. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study) , 1998, The American journal of cardiology.
[6] A. Gotto,et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.
[7] G. Thorgeirsson,et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S) , 1998, Circulation.
[8] P. Macfarlane,et al. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). , 1998, Circulation.
[9] B. Davis,et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. , 1998, Circulation.
[10] W. Kleophas,et al. LDL hemoperfusion--a new procedure for LDL apheresis: first clinical application of an LDL adsorber compatible with human whole blood. , 2008, Artificial organs.
[11] S. MacMahon,et al. Use of the Friedewald formula to estimate LDL-cholesterol in patients with chronic renal failure on dialysis. , 1997, Clinical chemistry.
[12] Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. , 1997, The New England journal of medicine.
[13] A. von Eckardstein,et al. Multicenter evaluation of a homogeneous assay for HDL-cholesterol without sample pretreatment. , 1997, Clinical chemistry.
[14] B. Davis,et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.
[15] E. Rimm,et al. Analytical performance and clinical utility of a direct LDL-cholesterol assay in a hyperlipidemic pediatric population. , 1996, Clinical chemistry.
[16] T. Bosch. Low-density lipoprotein hemoperfusion using a modified polyacrylate adsorber: in vitro, ex vivo, and first clinical results. , 1996, Artificial organs.
[17] M Nauck,et al. Quantitative determination of high-, low-, and very-low-density lipoproteins and lipoprotein(a) by agarose gel electrophoresis and enzymatic cholesterol staining. , 1995, Clinical chemistry.
[18] P. Macfarlane,et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .
[19] P. Bachorik,et al. National Cholesterol Education Program recommendations for measurement of low-density lipoprotein cholesterol: executive summary. The National Cholesterol Education Program Working Group on Lipoprotein Measurement. , 1995, Clinical chemistry.
[20] P. Macfarlane,et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. , 1995, The New England journal of medicine.
[21] L. Wilkins. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). , 1994 .
[22] J. Joven,et al. Limitations of the Friedewald formula for estimating low-density lipoprotein cholesterol in alcoholics with liver disease. , 1994, Clinical chemistry.
[23] N J Wald,et al. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? , 1994, BMJ.
[24] M. Sentí,et al. Calculated Low-Density Lipoprotein Cholesterol Should Not Be Used for Management of Lipoprotein Abnormalities in Patients With Diabetes Mellitus , 1993, Diabetes Care.
[25] N. Rifai,et al. Current recommendations of the Adult Treatment Panel and the Children and Adolescents Treatment Panel of the National Cholesterol Education , 2004 .
[26] C. Wanner,et al. Effects of HMG-CoA reductase inhibitors in hypercholesterolemic patients on hemodialysis. , 1991, Kidney international.
[27] J. Joven,et al. Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome. , 1990, The New England journal of medicine.
[28] P. Wilson,et al. Calculated values for low-density lipoprotein cholesterol in the assessment of lipid abnormalities and coronary disease risk. , 1990, Clinical chemistry.
[29] G. R. Warnick,et al. Estimating low-density lipoprotein cholesterol by the Friedewald equation is adequate for classifying patients on the basis of nationally recommended cutpoints. , 1990, Clinical chemistry.
[30] E. DeLong,et al. A comparison of methods for the estimation of plasma low- and very low-density lipoprotein cholesterol. The Lipid Research Clinics Prevalence Study. , 1986 .
[31] W. März,et al. Analysis of plasma lipoproteins by ultracentrifugation in a new fixed angle rotor: evaluation of a phosphotungstic acid/MgCl2 precipitation and a quantitative lipoprotein electrophoresis assay. , 1986, Clinica chimica acta; international journal of clinical chemistry.
[32] W Bablok,et al. Comparison of Several Regression Procedures for Method Comparison Studies and Determination of Sample Sizes Application of linear regression procedures for method comparison studies in Clinical Chemistry, Part II , 1984, Journal of clinical chemistry and clinical biochemistry. Zeitschrift fur klinische Chemie und klinische Biochemie.
[33] R. Levy,et al. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.